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When Robert Koch published his groundbreaking 
paper on the aetiology of tuberculosis (TB) in 1882, he 
reported that about a third of the working population 
died of TB [1]. World TB Day today should remind us not 
only about the first identification of the tubercle bacil-
lus but also that the main burden of the TB epidemic 
has shifted from Europe to other regions in the world. 
The 329,391 reported TB cases in the WHO European 
Region in 2009 contribute only 5.6% of all newly 
detected TB cases and relapses in the world, according 
to the latest report Tuberculosis surveillance in Europe 
2009, jointly published by the European Centre for 
Disease Prevention and Control (ECDC) and the WHO 
Regional Office for Europe [2]. Furthermore a sustained 
decline in TB can be noted with a mean annual reduc-
tion of 3.8% between 2005 and 2009, mainly attribut-
able to the high- and intermediate-burden countries in 
the European Union (EU) and European Economic Area 
(EAA).
Efforts to build a comprehensive TB surveillance sys-
tem in Europe date back 15 years, when recommenda-
tions for uniform reporting of TB were published in 1996 
in the first issue of Eurosurveillance by an expert group 
including governmental and non-governmental rep-
resentatives from 37 countries [3]. The system estab-
lished has allowed developments to be monitored: 
despite the reassuring overall decline in TB incidence, 
several challenges lurk in these data, as the analysis 
by Hollo et al. in this issue reveals [4]. Their data show 
a marked geographic heterogeneity: some countries in 
the EU/EAA belong in the group with the highest pro-
portions of multidrug-resistant TB in the world; also 
alarming proportions of patients lost to follow-up are 
observed and declining rates of culture confirmation of 
cases.
For the first time, the epidemiology of TB in children 
within the EU/EAA is put in the spotlight by Sandgren 
et al. [5]. Analysis of 10 years’ data on this neglected 
aspect of TB shows that about half of the TB cases 
in children were less than five years of age. The inci-
dence in this age group was higher than for children 
aged 5–14 years and the average annual percentage 
change in notification rates for 1–4 year-olds in low-
incidence countries (defined as incidence less than 20 
per 100,000 population) increased between 2000 and 
2009 by 7.4%. Even though it remains unclear if this 
rise is due to an overall increase in the risk of infection 
in the population or is the result of recent transmission 
in outbreaks, it shows that TB prevention and control 
does not reach those in the most vulnerable age group 
in Europe. This is supported by the fact that the overall 
treatment success of 75% for culture-confirmed pae-
diatric TB cases in low-incidence countries was well 
below the 85% WHO target and almost one third of chil-
dren were lost to follow-up in 2008. The true burden of 
disease in children, however, remains unclear as only 
16.9% of all cases in this analysis were confirmed by 
culture showing, as the authors conclude, that there is 
an urgent need to address TB diagnosis in children.
The occurrence of TB in children can serve as a marker 
for recent transmission, but at the same time, it also 
represents a failure of public health prevention [6]. 
For decades Bacillus Calmette-Guérin (BCG) vaccina-
tion has been a main element of prevention of primary 
TB in children; however, the efficacy of the vaccine 
varies substantially between different countries and 
regions worldwide [7]. Thus several low-incidence 
countries in Europe have revised their BCG policies in 
recent years, moving from universal to selective vac-
cination. Guthmann et al. report in this issue on two 
major changes in BCG vaccination in France, concern-
ing vaccine administration technique and the introduc-
tion of a selective vaccination policy in 2007 [8]. The 
authors looked at vaccination coverage and TB inci-
dence in two types of settings: a high-incidence area 
of the country with a policy of universal vaccination in 
comparison with other areas that have selective vacci-
nation targeting high-risk children. While no difference 
in TB rates in children under three years of age was 
found, the authors demonstrated a notable decline in 
vaccination coverage, mainly due to the vaccination 
technique. Although detailed data on BCG vaccination 
coverage are regularly retrieved and published by WHO 
(for 2009, see [9), data on the use of chemotherapy to 
prevent TB in children aged under five years in Europe 
are lacking. As Leung et al. point out, the efficacy of 
preventive isoniazid therapy for 6–12 months has been 
shown to reach 90%; however, acceptance and adher-
ence are less than desired [10].
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A study by Abubakar et al. in this issue describes a 
large outbreak investigation in the United Kingdom 
(UK) that demonstrates the contribution of interferon 
gamma release assays (IGRA) to active case finding 
and to our understanding of the risk of transmission 
[11]. The authors report on the use of IGRA for diagno-
sis of TB in a large outbreak among college students 
in the UK, involving 2,284 students between October 
2008 and January 2009. In addition to being a close 
contact of the index case, travel to a high-prevalence 
area was independently associated with becoming a 
case.  While no information about the type of travel and 
potential exposure could be collected retrospectively, 
this study demonstrates that the extent of recent infec-
tion in young adults born and living in a low-incidence 
country may be underestimated.
As this studies shows, important progress has been 
made in recent years in diagnostic techniques for TB 
infection. Unfortunately, however, the same cannot be 
said for the diagnosis in children. While a large number 
of studies have been published over the past few years 
on the use of IGRAs, including sensitivity, specificity 
and positive predictive values, corresponding data for 
children in the especially vulnerable age group, under 
five years, are still scarce. This holds also true for new 
methods of molecular detection of TB. Data on the 
rapid molecular detection of active TB and rifampicin 
drug resistance – a method endorsed by WHO as a 
‘major milestone for global TB diagnosis’ [12] – have 
not been published for children, yet.
The studies in this special issue give insight into 
the epidemiological situation of TB in Europe 
and show that, despite the overall decreasing 
trend in incidence, transmission of TB is ongoing, 
even in low-incidence countries. Identification of 
Mycobacterium tuberculosis infection in children 
presents a key event allowing early recognition and at 
the same time intervention to prevent cases in children 
and adults. Even though the absolute number of active 
cases in children is much smaller than in adults, the 
risk of rapid progression to severe disease is much 
higher, adding a considerable burden to the health sys-
tem. In addition, every undetected child infected today 
has the potential to progress to an infectious case of 
TB for decades in the future. 
Thus, the elimination of tuberculosis requires a call 
for action [13], to put the focus on TB in children – it’s 
about time.
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